RGLSUnknownSmall-Cap

Regulus Therapeutics Inc. Insider Trading Activity

Every SEC Form 4 insider transaction reported for Regulus Therapeutics Inc. (RGLS), sourced directly from SEC EDGAR and updated as new filings are accepted.

Last updated:

Quick Answer

Are RGLS insiders buying or selling?

Regulus Therapeutics Inc. insiders reported 38 open-market buys ($45.0M) and 36 sells ($497.3K) across 74 Form 4 filings — a net buying position of $44.5M.

Source: SEC EDGAR Form 4

Key Statistics (as of Jun 4, 2025)

Total Form 4 filings
74
SEC EDGAR
Insider filers
23
Insider buys (38)
$45.0M
Insider sells (36)
$497.3K

Insider sentiment

Net buying

Net insider flow of $44.5M in net buying.

Recent RGLS insider transactions

DateInsiderRoleTypeSharesPriceValue
Jun 4, 2025Preston KlassenPresident & Head of R & DPurchase12.0K$7.99$95.9K
Jan 31, 2025Joseph P HaganChief Executive OfficerPurchase50.0K$1.09$54.3K
Jan 31, 2025David BaltimoreDirectorPurchase19.6K$1.06$20.8K
Jan 15, 2025Christopher Ray AkerSr. VP & General CounselSale43.6K$1.26$55.1K
Jan 15, 2025Joseph P HaganChief Executive OfficerSale127.1K$1.26$160.5K
Jan 15, 2025Crispina CalsadaChief Financial OfficerSale43.8K$1.26$55.3K
Jan 15, 2025Preston KlassenPresident & Head of R & DSale31.4K$1.26$39.7K
Jul 29, 2024Kathryn J CollierDirectorPurchase4.0K$1.82$7.3K
Jan 19, 2024Crispina CalsadaChief Financial OfficerSale5.5K$1.19$6.5K
Jan 19, 2024Christopher Ray AkerSr. VP & General CounselSale5.5K$1.19$6.5K
Jan 19, 2024Joseph P HaganChief Executive OfficerSale14.6K$1.19$17.4K
Mar 1, 2022Denis DryginChief Scientific OfficerPurchase76.7K$0.23$17.6K
Feb 7, 2022Denis DryginChief Scientific OfficerPurchase23.3K$0.23$5.4K
Jan 26, 2022Joseph P HaganPresident and CEOPurchase100.0K$0.22$21.5K
May 17, 2021Joseph P HaganPresident and CEOSale4.2K$0.89$3.7K
Apr 16, 2021Joseph P HaganPresident and CEOSale4.1K$1.72$7.1K
Feb 17, 2021Christopher Ray AkerSr. VP & General CounselSale828$1.72$1.4K
Feb 17, 2021Joseph P HaganPresident and CEOSale4.1K$1.72$7.1K
Dec 7, 2020Paul Edward Walker10% OwnerPurchase4.4M$0.62$2.7M
Dec 7, 2020Peter W. Sonsini10% OwnerPurchase4.4M$0.62$2.7M
Dec 7, 2020Scott D Sandell10% OwnerPurchase4.4M$0.62$2.7M
Dec 7, 2020Joshua Makower10% OwnerPurchase4.4M$0.62$2.7M
Dec 7, 2020Mohamad Makhzoumi10% OwnerPurchase4.4M$0.62$2.7M
Dec 7, 2020Anthony A. Florence Jr.10% OwnerPurchase4.4M$0.62$2.7M
Dec 7, 2020Carmen Chang10% OwnerPurchase4.4M$0.62$2.7M

Showing the 25 most recent of 74 Form 4 filings for Regulus Therapeutics Inc..

Most active RGLS insiders

  • Joseph P Hagan19 filings
  • Christopher Ray Aker14 filings
  • Stelios Papadopoulos4 filings
  • Daniel R. Chevallard3 filings
  • Paul Edward Walker3 filings

Ask anything about RGLS insider activity

Use Trabud's AI agent to query Regulus Therapeutics Inc.'s Form 4 history in plain English — "Show me RGLS CEO purchases this year" or compare it against any other ticker.

Open the AI agent

RGLS insider trading FAQ

Are Regulus Therapeutics Inc. insiders buying or selling?

Across 74 SEC Form 4 filings, Regulus Therapeutics Inc. (RGLS) insiders reported 38 open-market purchases totaling $45.0M and 36 sales totaling $497.3K. That is a net buying position of $44.5M.

How many insiders trade RGLS stock?

23 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Regulus Therapeutics Inc.. The most recent filing was accepted on Jun 4, 2025.

Where does Trabud get RGLS insider trading data?

All RGLS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.

Looking for another company? Browse all tracked companies.

Related Content